Background: Capecitabine is an approved standard therapy for anthracycline-and taxane-pretreated locally advanced or metastatic breast cancer (BC). Vinflunine has demonstrated single-agent activity in phase II studies in this setting and activity and tolerability when combined with capecitabine. We compared the combination of vinflunine plus capecitabine (VC) with single-agent capecitabine. ) q3w. The primary end point was progression-free survival (PFS) assessed by an independent review committee. The study had 90% power to detect a 30% improvement in PFS.
Introduction
Breast cancer is the most prevalent cancer in women worldwide [1] and the leading cause of cancer-related deaths in women in Europe and globally [2, 3] . Anthracyclines and taxanes are among the most active chemotherapy agents for breast cancer and are widely used as primary therapy. Consequently, many patients presenting with metastatic breast cancer (MBC) have already received anthracyclines and taxanes and these agents are no longer a treatment option because of resistance or cumulative toxicities.
For more than a decade, the oral fluoropyrimidine capecitabine was the only approved treatment for anthracycline-and taxane-pretreated MBC. Most phase III trials in pretreated MBC have failed to show improved outcomes with novel agents combined or compared with capecitabine [4] [5] [6] [7] ; only the combination of ixabepilone and capecitabine was superior to capecitabine alone in this setting, but at the expense of considerable toxicity [8, 9] . More recently, single-agent eribulin was approved for advanced breast cancer progressing after at least two chemotherapeutic regimens for advanced/metastatic disease, including anthracycline and taxane therapy. Eribulin significantly improved overall survival (OS) compared with investigators' treatment of choice in the EMBRACE trial [10] . However, progression-free survival (PFS) was not improved and grade 3 haematological toxicity and peripheral neuropathy were increased with eribulin. A second phase III trial showed no improvement in OS or PFS with eribulin versus capecitabine [11] .
Several phase II/III trials exploring capecitabine combined with vinorelbine, a vinca alkaloid, have demonstrated activity of the regimen in the first-line setting and in pretreated MBC [12] . Vinflunine, another vinca alkaloid, appeared to be more potent than vinorelbine in preclinical models [13] . Subsequent phase II studies demonstrated single-agent activity in anthracycline-and taxane-pretreated MBC, including taxane-resistant disease [14, 15] . Based on preclinical synergy with 5-fluorouracil [16] and non-overlapping toxicities, vinflunine was evaluated in combination with capecitabine in MBC, showing a 44% overall response rate (ORR) [17] . The main toxicity was neutropenia. A regimen of vinflunine 280 mg/m 2 on day 1 and capecitabine 825 mg/m 2 twice daily (b.i.d.) on days 1-14 every 3 weeks (q3w) was recommended for further evaluation. Consequently, we initiated a randomised phase III trial comparing this regimen with singleagent capecitabine in patients with taxane-resistant anthracycline-pretreated/anthracycline-resistant locally advanced or MBC.
Patients and methods

Study design
In this international open-label randomised phase III trial, eligible patients were randomly assigned 1 : 1 to receive vinflunine plus capecitabine (VC) or capecitabine alone. Stratification factors were as follows: resistance to anthracyclines (yes versus no), Karnofsky performance score (KPS; 90/100 versus 70/80), measurable disease (yes versus no), number of prior chemotherapy lines for metastatic disease (0 versus 1 versus >1) and study site.
Eligibility
Women aged 21-80 years with unresectable histologically or cytologically confirmed locally recurrent or MBC were eligible. Disease had to be taxane resistant [disease progression during therapy, or within 4 months of the last dose for MBC, or within 12 months in the (neo)adjuvant setting] and either resistant to an anthracycline (defined as above) or previously treated with a cumulative anthracycline dose of 180 mg/m 2 doxorubicin or 300 mg/m 2 epirubicin. Endocrine therapy and human epidermal growth factor receptor 2-directed therapy had to be discontinued 2 and 3 weeks, respectively, before randomisation. Patients had to have adequate haematological, hepatic, renal and cardiac function, a KPS of 70% and an estimated life expectancy of 12 weeks.
Exclusion criteria included clinical evidence of brain metastasis or leptomeningeal involvement, pre-existing grade 2 motor or sensory peripheral neuropathy according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; version 3.0), more than three prior chemotherapy regimens, prior capecitabine and/or vinca alkaloid therapy (including vinflunine), uncontrolled hypercalcaemia, congestive heart failure, uncontrolled high-risk hypertension, arrhythmia, or angina pectoris, or previous history of myocardial infarction within 6 months before randomisation.
All patients provided written informed consent before undergoing any study-specific procedures. The study was conducted in accordance with the principles of the Declaration of Helsinki and subsequent amendments and the Good Clinical Practice Guidelines. The protocol and study-related documents were approved by an independent ethics committee.
Treatment
In the combination arm, patients received i. 
End points and assessments
The primary end point was PFS in the intent-to-treat (ITT) population, as assessed by a blinded independent review committee (IRC). Secondary end points included (unconfirmed) ORR, disease control rate (DCR; response or stable disease), duration of response, time to treatment failure, time to first response, OS, quality of life (QoL) and safety.
Tumour response was assessed every 6 weeks from randomisation until documented disease progression according to Response Evaluation Criteria in Solid Tumours (version 1.1). Additional imaging was carried out if clinically indicated. A blinded IRC reviewed computed tomography and magnetic resonance imaging scans to determine PFS.
QoL was evaluated using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire core module (QLQ-C30) and Quality of Life Questionnaire breast cancer-specific module (QLQ-BR23) completed before randomisation, before cycle 3, then every two cycles and at the treatment discontinuation visit. Adverse events (AEs) were graded according to NCI CTCAE (version 3.0).
Statistical analysis
PFS events in 615 patients provided 90% power with a two-sided log-rank test (a ¼ 0.05) to detect a hazard ratio (HR) of 0.77, assuming a median PFS of 3 months with capecitabine alone. A total of 764 randomised patients were required, assuming 10% loss to follow-up and a 30-month recruitment period. The final OS analysis was prespecified after at least 631 patients had died, providing 80% power to detect an OS difference assuming an HR of 0.80 and median OS of 10 months with capecitabine alone.
Time-dependent end points were described using Kaplan-Meier methodology. HRs were estimated using a stratified Cox proportional hazards model; medians [with 95% confidence intervals (CIs)] were calculated using the Brookmeyer-Crowley method. QoL questionnaires were scored according to the EORTC recommendations and scoring manuals.
All statistical tests were two sided at the 5% significance level unless otherwise specified. Analyses were conducted using SAS 9.3 (Statistical Analysis System, Cary, NC). (Table 1) .
Results
Patient population
Treatment exposure
The median number of treatment cycles was 6 (range, 1-35) in the combination arm and 5 (range, 1-33) in the monotherapy arm. The median relative dose intensity (RDI) of vinflunine was 98.6%, with 78% of all cycles given at >90% RDI. The median RDI of capecitabine was 94.1% in the combination arm and 92.1% in the monotherapy arm.
In the combination arm, 50 patients (13%) had at least one vinflunine dose reduction (most often because of neutropenia, febrile neutropenia or constipation) and 73 patients (19%) had at least one capecitabine dose reduction (most often for hand-foot syndrome or anaemia). In the monotherapy arm, 129 patients (33%) had at least one capecitabine dose reduction (predominantly for hand-foot syndrome, some for diarrhoea). At least one cycle was delayed in more patients in the monotherapy arm (44%) than the combination arm (39%). Conversely, capecitabine doses were omitted more frequently in the combination arm (34%) than in the monotherapy arm (22%).
Efficacy
The cut-off date for the primary PFS analysis was 20 December 2011. IRC-assessed PFS was significantly superior in the combination arm (HR ¼ 0.84; 95% CI, 0.71-0.99; log-rank P ¼ 0.043; Figure 2A ). Median PFS was 5.6 months with VC versus 4.3 months with capecitabine alone. Investigator-assessed PFS results were similar [HR ¼ 0.77 (95% CI, 0.66-0.90), P ¼ 0.0012; median 5.5 versus 4.1 months with VC versus capecitabine alone, respectively]. Sensitivity analyses (including further anti-cancer therapy as an event, censoring at start of new therapy, or censoring at last assessment showing no progression) supported the primary results.
Time to treatment failure was significantly longer with VC than with capecitabine (median 4.2 versus 3.6 months, respectively; HR ¼ 0.80; 95% CI, 0.69-0.93; log-rank P ¼ 0.0040).
In the 628 patients with measurable disease, there was no difference in IRC-assessed ORR [27% (95% CI, 22% to 32%) with VC versus 23% (95% CI 18% to 27%) with capecitabine alone; P ¼ 0.27). However, IRC-assessed DCR was significantly higher All randomised patients (intent-to-treat population). b Treated with at least two cycles of study treatment (unless progression was documented or the patient died before the second cycle) with one tumour assessment after cycle 2.
c All treated patients.
d Patients with one baseline and one on-study QoL assessment. IRC, independent review committee; QoL, quality of life. OS was analysed after 643 deaths (84%) in the ITT population (data cut-off: 15 March 2013). There was no statistically significant difference in OS between treatment arms ( Figure 2B ). Updated investigator-assessed PFS at this time was consistent with results from the primary PFS analysis (HR ¼ 0.77; 95% CI, 0.66-0.90; log-rank P ¼ 0.0007).
Most patients (61% VC, 66% capecitabine alone) received another treatment, predominantly chemotherapy, after discontinuing 
Quality of life
Approximately two-thirds of patients were evaluable for QoL. Global QoL (QLQ-C30) showed no difference between treatment arms from baseline throughout therapy. Similarly, no difference was observed between treatment arms for change in symptom scale scores over time according to QLQ-BR23. Table 2 shows the most common AEs. Neutropenia (all grades and grade 3/4) was more frequent with VC than capecitabine alone; treatment-related febrile neutropenia occurred in 2% versus 0.5% of patients, respectively. Colony-stimulating factors were used in 11% of patients receiving combination therapy and 2% of those receiving monotherapy.
Safety
Non-haematological drug-related AEs were more common with combination therapy than with monotherapy, except for diarrhoea, hand-foot syndrome and dyspnoea. The most frequently reported grade 3/4 non-haematological AEs with VC were fatigue, abdominal pain, hand-foot syndrome, asthenia, constipation and dyspnoea. Laxatives were administered in 66% of patients in the combination arm and anti-emetics in 43% (versus 12% and 14%, respectively, in the monotherapy arm). Corticosteroids were administered in 92% of patients in the combination arm versus 18% in the capecitabine-alone arm. In the monotherapy arm, the most frequent grade 3/4 nonhaematological AEs were hand-foot syndrome, diarrhoea, dyspnoea and fatigue. Grade 3 peripheral neuropathy was uncommon (<2%) in both arms. There were three fatal AEs: two patients (0.5%) in the combination arm (grade 4 febrile neutropenia leading to death from septic shock in both patients on days 7 and 12 of cycle 1) and one patient (0.3%) in the capecitabinealone arm (hypovolaemic shock in the context of diarrhoea on According to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0), except for hand-foot syndrome, which was graded according to the criteria in the capecitabine Summary of Product Characteristics. NA, not applicable. day 4; dihydropyrimidine dehydrogenase deficiency was suspected but not confirmed).
Discussion
VC showed superior IRC-assessed PFS compared with capecitabine alone, thus meeting the primary objective of this phase III trial. The 4.3-month median PFS with capecitabine alone was longer than anticipated based on initial single-arm studies (reviewed by Seidman et al. [18] ) but was consistent with more recent phase III data in this setting [4, 5, 8, 9, 11] , presumably reflecting improved diagnosis and supportive treatment over time. PFS and OS with VC are within the range reported in single-arm studies of vinorelbine plus capecitabine in anthracycline-and taxane-pretreated MBC [12] . The PFS benefit from vinflunine did not translate into significantly improved OS, nor did the improvement in ORR reach statistical significance. Consistent with the known safety profile of vinflunine, haematological toxicity was the main adverse effect reported with VC. Grade 3 neutropenia occurred in 28% of patients but febrile neutropenia was observed in only 2% (although in two patients, this subsequently resulted in death). Constipation, a class effect of vinca alkaloids, occurred at grade 3 in only 3% of patients receiving combination therapy, much lower than the rate observed with single-agent vinflunine in urothelial carcinoma [19] . The frequent use of prophylactic laxatives may have contributed to the lower incidence in our study, as may the generally better condition of patients and absence of pelvic disease in this MBC population.
The substantially lower incidence of hand-foot syndrome with the combination regimen (25%, versus 47% with capecitabine alone) was probably due to the lower capecitabine dose. The 18% incidence of grade 3 hand-foot syndrome with monotherapy is within the 14%-26% range reported in contemporary phase III trials using an identical control arm regimen [5, 6, 8, 9, 11, 20] but higher than in several trials (predominantly of first-line therapy with longer treatment exposure) using a starting dose of 1000 mg/m 2 b.i.d. (7%-15%) [7, 21, 22] . However, there are no conclusive data showing that reducing the starting dose of singleagent capecitabine does not affect efficacy [23] .
Although sequential single-agent therapy is usually preferred except in patients requiring a high likelihood of response, an alternative approach is to combine a lower dose of capecitabine with another active yet tolerable agent. This strategy provided sustained disease control with a lower incidence of hand-foot syndrome in our trial. The tolerability of the VC combination was reflected in patient-reported QoL results.
The same approach was adopted in the recently published Chinese BG01-1323L phase III trial comparing utidelone (an epothilone analogue) plus capecitabine (1000 mg/m 2 b.i.d., days 1-14) versus capecitabine alone (1250 mg/m 2 b.i.d., days 1-14) in patients with heavily pretreated MBC (refractory to anthracyclines and taxanes) [24] . IRC-assessed PFS (primary end point) was significantly superior in the combination arm (HR ¼ 0.46; median 8.4 versus 4.3 months with capecitabine alone). The combination regimen was associated with a high incidence of grade 3 peripheral neuropathy (22% versus <1% in the capecitabinealone arm). Interestingly, grade 3 hand-foot syndrome occurred at a similar incidence in the two treatment arms (7% with utidelone/capecitabine versus 8% with capecitabine alone). However, comparison of this incidence in a Chinese population with our observations for VC is complicated because of recognised and widely reported differences in the tolerability of fluoropyrimidines in Asian versus non-Asian populations.
In conclusion, our results provide evidence that the VC combination offers improved PFS and DCR compared with capecitabine monotherapy in taxane-resistant anthracyclinepretreated/-resistant MBC, and appears to be better tolerated than other regimens used in the same setting, especially with regard to neurotoxicity and hand-foot syndrome.
